Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.68 |
| ▸ | NPC1 | O15118 | 6/20 | 0.68 |
| ▸ | RAB9A | P51151 | 6/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.68 |
| ▸ | RELA | Q04206 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 5/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | TACR2 | P21452 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414613 | 0.88 | TACR2 (0.70) | SMN1; SMN2NPC1RAB9ANFKB1NFKB2 | |
| SCHEMBL560188 | 0.88 | MAOA (0.56) | SMN1; SMN2NPC1RAB9ANFKB1NFKB2 | |
| SCHEMBL29446267 | 0.85 | TACR2 (0.62) | SMN1; SMN2NPC1RAB9AHPGDMAOA | |
| SCHEMBL584489 | 0.85 | TACR2 (0.62) | SMN1; SMN2NPC1RAB9AHPGDMAOA | |
| SCHEMBL23496294 | 0.85 | TACR2 (0.59) | SMN1; SMN2NPC1RAB9ANFKB1NFKB2 | |
| SCHEMBL15774354 | 0.85 | CISD1 (0.58) | SMN1; SMN2NPC1RAB9ANFKB1NFKB2 | |
| SCHEMBL1299319 | 0.85 | HPGD (0.61) | SMN1; SMN2NPC1RAB9ANFKB1NFKB2 | |
| SCHEMBL12516172 | 0.84 | RAB9A (0.68) | SMN1; SMN2NPC1RAB9ANFKB1NFKB2 | |
| SCHEMBL15774835 | 0.84 | MAOA (0.63) | SMN1; SMN2NPC1RAB9ANFKB1NFKB2 | |
| SCHEMBL5216320 | 0.84 | TACR2 (0.78) | SMN1; SMN2NPC1RAB9ANFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| EP-4214189-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL Business Ltd (GB) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022058733-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS PLC (GB) | 2022-03-24 | — | — | WO | disclosed |
| EP-3928779-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | Chugai Seiyaku Kabushiki Kaisha (JP) | 2021-12-29 | — | — | EP | disclosed |
| EP-3192511-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-107072993-B | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | 中外制药株式会社 | 2021-02-12 | — | — | CN | disclosed |
| US-6683095-B2 | ANTICARCINOGENIC AGENTS; ANTIPROLIFERATION AGENTS | LG LIFE SCIENCES LTD. (KR) | 2004-01-27 | — | — | US | disclosed |
| WO-2004007453-A1 | PIPERIDINETRIOL DERIVATIVES AS INHIBITORS OF GLYCOSYLCERAMIDE SYNTHASE | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2004-01-22 | — | — | WO | disclosed |
| CN-1433410-A | CDK inhibitors having 3-hydroxychromen-4-one structure | LG LIFE SCIENCES CO LTD (KR) | 2003-07-30 | — | — | CN | disclosed |
| US-20030125356-A1 | Cdk inhibitors having 3-hydroxychromen-4-one structure | LG LIFE SCIENCES LTD. (KR) | 2003-07-03 | — | — | US | disclosed |
| EP-1280789-A1 | CDK INHIBITORS HAVING 3-HYDROXYCHROMEN-4-ONE STRUCTURE | LG Life Sciences Ltd. (KR) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001083469-A1 | CDK INHIBITORS HAVING 3-HYDROXYCHROMEN-4-ONE STRUCTURE | LG LIFE SCIENCES LTD. (KR) | 2001-11-08 | — | — | WO | disclosed |
| US-4649160-A | HYPOTENSIVE, ANTIARRHYTHMIA, ADRENERGIC BLOCKING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1987-03-10 | — | — | US | disclosed |
| EP-0066351-B1 | ARYLETHANOL AMINE DERIVATIVES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1985-06-26 | — | — | EP | disclosed |
| EP-0066351-A1 | Arylethanol amine derivatives, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1982-12-08 | — | — | EP | disclosed |
| EP-0041233-A1 | Substituted phenoxy-aminopropanol derivatives, intermediates and processes for their production, and pharmaceutical preparations containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125356-A1 | Cdk inhibitors having 3-hydroxychromen-4-one structure | CDK4, CDK3, CDK6 | SMN1; SMN2 4162/4885NPC1 4376/4885RAB9A 4302/4885 |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | TTR, C1R, APOB | SMN1; SMN2 1033/4885NPC1 1272/4885RAB9A 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.